Mendus AB (Sweden) Analysis
| IMMU Stock | SEK 7.25 0.30 3.97% |
Mendus AB is overvalued with Real Value of 6.78 and Hype Value of 7.25. The main objective of Mendus AB stock analysis is to determine its intrinsic value, which is an estimate of what Mendus AB is worth, separate from its market price. There are two main types of Mendus AB's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Mendus AB's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Mendus AB's stock to identify patterns and trends that may indicate its future price movements.
The Mendus AB stock is traded in Sweden on Stockholm Exchange, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Sweden. Mendus AB is usually not traded on All Saints ' Day, St . John 's Day, Christmas Eve, Christmas Day, Boxing Day, New Year 's Day, Epiphany, Good Friday, Easter Sunday, Easter Monday, International Workers ' Day, NationalDay. Mendus Stock trading window is adjusted to Europe/Stockholm timezone.
Mendus |
Mendus Stock Analysis Notes
About 58.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.13. Some equities with similar Price to Book (P/B) outperform the market in the long run. Mendus AB recorded a loss per share of 0.63. The entity had not issued any dividends in recent years. The firm had 20:1 split on the 3rd of June 2024. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden. To learn more about Mendus AB call the company at 46 87 32 84 00 or check out https://www.mendus.com.Mendus AB Investment Alerts
| Mendus AB generated a negative expected return over the last 90 days | |
| Mendus AB has high historical volatility and very poor performance | |
| Net Loss for the year was (130.1 M) with profit before overhead, payroll, taxes, and interest of 6 K. | |
| Mendus AB has accumulated about 155.31 M in cash with (138.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.94. | |
| Roughly 58.0% of the company shares are held by company insiders |
Mendus Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 427.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mendus AB's market, we take the total number of its shares issued and multiply it by Mendus AB's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 31st of January, Mendus AB secures the Standard Deviation of 4.78, mean deviation of 3.07, and Risk Adjusted Performance of 5.0E-4. Mendus AB technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.Mendus AB Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Mendus AB middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Mendus AB. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Mendus AB Outstanding Bonds
Mendus AB issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mendus AB uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mendus bonds can be classified according to their maturity, which is the date when Mendus AB has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Mendus AB Predictive Daily Indicators
Mendus AB intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mendus AB stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 6874.14 | |||
| Daily Balance Of Power | (0.41) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 6.88 | |||
| Day Typical Price | 7.0 | |||
| Price Action Indicator | 0.22 | |||
| Period Momentum Indicator | (0.30) |
Mendus AB Forecast Models
Mendus AB's time-series forecasting models are one of many Mendus AB's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mendus AB's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Mendus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Mendus AB prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mendus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Mendus AB. By using and applying Mendus Stock analysis, traders can create a robust methodology for identifying Mendus entry and exit points for their positions.
Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Mendus AB to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.